BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang N, Xu H, Ren AH, Zhang Q, Yang DW, Ba T, Wang ZC, Yang ZH. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation? J Magn Reson Imaging 2021. [PMID: 33963801 DOI: 10.1002/jmri.27688] [Reference Citation Analysis]
2 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shin J, Lee S, Yoon JK, Chung YE, Choi J, Park M. LI‐RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. J Magn Reson Imaging 2021;54:518-25. [DOI: 10.1002/jmri.27570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Laroia ST, Yadav K, Kumar S, Rastogi A, Kumar G, Sarin SK. Material decomposition using iodine quantification on spectral CT for characterising nodules in the cirrhotic liver: a retrospective study. Eur Radiol Exp 2021;5:22. [PMID: 34046753 DOI: 10.1186/s41747-021-00220-6] [Reference Citation Analysis]
5 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
6 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
7 Fung A, Shanbhogue KP, Taffel MT, Brinkerhoff BT, Theise ND. Hepatocarcinogenesis: Radiology-Pathology Correlation. Magn Reson Imaging Clin N Am 2021;29:359-74. [PMID: 34243923 DOI: 10.1016/j.mric.2021.05.007] [Reference Citation Analysis]
8 Kim YY, Kim YK, Min JH, Cha DI, Kim JM, Choi GS, Ahn S. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents. Korean J Radiol 2021;22:725-34. [PMID: 33660458 DOI: 10.3348/kjr.2020.1143] [Reference Citation Analysis]
9 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 30.0] [Reference Citation Analysis]
11 Zhang GX, Liu YL, Yang M, Huang WS, Xu JH. An aptamer-based, fluorescent and radionuclide dual-modality probe. Biochimie 2020;171-172:55-62. [PMID: 32081705 DOI: 10.1016/j.biochi.2020.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Korean J Radiol 2021;22:1066-76. [PMID: 33739633 DOI: 10.3348/kjr.2020.0846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Lee S, Kim SS, Bae H, Shin J, Yoon JK, Kim MJ. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI. Eur Radiol 2021;31:855-63. [PMID: 32809162 DOI: 10.1007/s00330-020-07146-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clinical Imaging 2020;62:63-8. [DOI: 10.1016/j.clinimag.2020.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
16 Kim SS, Lee S, Choi JY, Lim JS, Park MS, Kim MJ. Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas. Abdom Radiol (NY) 2020;45:3743-54. [PMID: 32377757 DOI: 10.1007/s00261-020-02562-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [Reference Citation Analysis]
18 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lee S, Kim KW, Jeong WK, Jeong SY, Hwang JA, Choi JS, Lee SG, Joh JW. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study. Ann Surg Oncol 2021. [PMID: 33751296 DOI: 10.1245/s10434-021-09772-8] [Reference Citation Analysis]
21 Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zopfs D, Graffe J, Reimer RP, Schäfer S, Persigehl T, Maintz D, Borggrefe J, Haneder S, Lennartz S, Große Hokamp N. Quantitative distribution of iodinated contrast media in body computed tomography: data from a large reference cohort. Eur Radiol 2021;31:2340-8. [PMID: 32997173 DOI: 10.1007/s00330-020-07298-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Kong Y, Jing Y, Sun H, Zhou S, M.a B. The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer. Journal of Healthcare Engineering 2022;2022:1-10. [DOI: 10.1155/2022/5074571] [Reference Citation Analysis]
24 Lee SM, Lee JM, Ahn SJ, Kang H, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI. Radiology 2019;292:655-63. [DOI: 10.1148/radiol.2019182867] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
25 Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ah Hwang J, Wook Kang T, Hye Min J, Kon Kim Y, Hyun Kim S, Hyun Sinn D, Kim K. Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110328] [Reference Citation Analysis]
28 Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lee HA, Goh HG, Lee YS, Jung YK, Kim JH, Yim HJ, Lee MG, An H, Jeen YT, Yeon JE, Byun KS, Seo YS. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol 2021;21:258. [PMID: 34118869 DOI: 10.1186/s12876-021-01833-2] [Reference Citation Analysis]
30 Liang Y, Xu F, Wang Z, Tan C, Zhang N, Wei X, Jiang X, Wu H. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Eur J Radiol 2022;153:110356. [PMID: 35623312 DOI: 10.1016/j.ejrad.2022.110356] [Reference Citation Analysis]
31 Cruz M, Ferreira AA, Papanikolaou N, Banerjee R, Alves FC. New boundaries of liver imaging: from morphology to function. Eur J Intern Med 2020;79:12-22. [PMID: 32571581 DOI: 10.1016/j.ejim.2020.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ma H, Hei A, Zhou J, He E, Skog S, Li J. Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis. Future Sci OA 2021;7:FSO717. [PMID: 34258026 DOI: 10.2144/fsoa-2021-0016] [Reference Citation Analysis]
35 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
36 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
37 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2021. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Reference Citation Analysis]
38 Sung PS, Jang JW, Lee J, Lee SK, Lee HL, Yang H, Nam HC, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK. Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Front Oncol. 2020;10:1043. [PMID: 32695681 DOI: 10.3389/fonc.2020.01043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Jaffe A, Schilsky ML, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: Barriers and Ethical considerations for Management and Next Steps. Hepatol Commun. 2020;. [PMID: 32838103 DOI: 10.1002/hep4.1568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Marschner CA, Zhang L, Schwarze V, Völckers W, Froelich MF, von Münchhausen N, Schnitzer ML, Geyer T, Fabritius MP, Rübenthaler J, Clevert DA. The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients1. Clin Hemorheol Microcirc 2020;76:453-8. [PMID: 33216017 DOI: 10.3233/CH-209221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
41 Kim TS, Lee M, Park M, Kim SY, Shim MS, Lee CY, Choi DH, Cho Y. Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1. Int J Mol Sci 2021;22:10027. [PMID: 34576192 DOI: 10.3390/ijms221810027] [Reference Citation Analysis]
42 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
43 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
44 Kim TH, Kim H, Joo I, Lee JM. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis. Korean J Radiol 2020;21:1115-25. [PMID: 32729276 DOI: 10.3348/kjr.2020.0091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Ren S, Qi Q, Liu S, Duan S, Mao B, Chang Z, Zhang Y, Wang S, Zhang L. Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: A multicenter study. Eur J Radiol 2021;143:109891. [PMID: 34481117 DOI: 10.1016/j.ejrad.2021.109891] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Wattanasatesiri T, Kim HC, Choi JW, Lee JH, Joo I, Hur S, Lee M, Jae HJ, Chung JW. Cone-Beam CT-Guided Chemoembolization in Patients with Complete Response after Previous Chemoembolization but Subsequent Elevated α-Fetoprotein without Overt Hepatocellular Carcinoma. J Vasc Interv Radiol 2019;30:1273-80. [PMID: 31235410 DOI: 10.1016/j.jvir.2019.03.020] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [DOI: 10.3748/wjg.v28.i27.3410] [Reference Citation Analysis]
49 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Kang JH, Choi SH, Kim SY, Lee SJ, Shin YM, Won HJ, Kim PN. US LI-RADS visualization score: diagnostic outcome of ultrasound-guided focal hepatic lesion biopsy in patients at risk for hepatocellular carcinoma. Ultrasonography 2021;40:167-75. [PMID: 32623854 DOI: 10.14366/usg.19066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, Tak WY, Park SY, Kim BK. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol 2021. [PMID: 34478195 DOI: 10.1111/jgh.15678] [Reference Citation Analysis]
52 Lee HW, Han DH, Shin HJ, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. Cancers (Basel) 2020;12:E3414. [PMID: 33217965 DOI: 10.3390/cancers12113414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Lee S, Kim YY, Shin J, Hwang SH, Roh YH, Chung YE, Choi JY. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. J Am Coll Radiol 2020;17:1199-206. [PMID: 32640250 DOI: 10.1016/j.jacr.2020.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Baek KA, Kim SS, Shin HC, Hwang JA, Choi SY, Lee WH, Park CH, Lee HN, Heo NH. Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout? Abdom Radiol (NY) 2020;45:2705-16. [PMID: 32382820 DOI: 10.1007/s00261-020-02553-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
56 Ciocalteu A, Iordache S, Cazacu SM, Urhut CM, Sandulescu SM, Ciurea AM, Saftoiu A, Sandulescu LD. Role of Contrast-Enhanced Ultrasonography in Hepatocellular Carcinoma by Using LI-RADS and Ancillary Features: A Single Tertiary Centre Experience. Diagnostics (Basel) 2021;11:2232. [PMID: 34943474 DOI: 10.3390/diagnostics11122232] [Reference Citation Analysis]
57 Tang A, Abukasm K, Moura Cunha G, Song B, Wang J, Wagner M, Dietrich CF, Brancatelli G, Ueda K, Choi JY, Aguirre D, Sirlin CB. Imaging of hepatocellular carcinoma: a pilot international survey. Abdom Radiol (NY) 2021;46:205-15. [PMID: 32488557 DOI: 10.1007/s00261-020-02598-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Lee SK, Chung DJ, Cho SH. A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma. J Clin Med 2022;11:302. [PMID: 35053997 DOI: 10.3390/jcm11020302] [Reference Citation Analysis]
59 Feng Z, Zhao H, Guan S, Wang W, Rong P. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis. Liver Int 2021;41:1117-28. [DOI: 10.1111/liv.14850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Brunsing RL, Fowler KJ, Yokoo T, Cunha GM, Sirlin CB, Marks RM. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res 2020;6:59. [PMID: 33381651 DOI: 10.20517/2394-5079.2020.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
61 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
62 Byun J, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 2020;14:534-43. [PMID: 32314171 DOI: 10.1007/s12072-020-10040-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
63 Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020;107:106-15. [PMID: 32084526 DOI: 10.1016/j.ijrobp.2020.01.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
64 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Ren S, Li Q, Liu S, Qi Q, Duan S, Mao B, Li X, Wu Y, Zhang L. Clinical Value of Machine Learning-Based Ultrasomics in Preoperative Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Multicenter Study. Front Oncol 2021;11:749137. [PMID: 34804935 DOI: 10.3389/fonc.2021.749137] [Reference Citation Analysis]
66 Nam H, Lee SW, Kwon JH, Lee HL, Yoo SH, Kim HY, Song DS, Sung PS, Chang UI, Kim CW, Nam SW, Bae SH, Choi JY, Yoon SK, Yang JM, Han NI, Jang JW. Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B. Am J Gastroenterol 2021;116:1657-66. [PMID: 33734114 DOI: 10.14309/ajg.0000000000001219] [Reference Citation Analysis]
67 Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, Choi JI, Lee CH, Park HS, Lee K, Kim H, Yu E, Kang HJ, Ha SY, Kim JY, Ahn S, Jung ES, Kim BH, Han HS, Lee JM. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296:335-45. [PMID: 32484414 DOI: 10.1148/radiol.2020192275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
68 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Kim YY, Lee S, Shin J, Son WJ, Roh YH, Hwang JA, Lee JE. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. Eur Radiol 2022. [PMID: 35849177 DOI: 10.1007/s00330-022-08985-z] [Reference Citation Analysis]
70 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Tak WY, Park JY, Kweon YO, Kim DY, Ahn SH, Jang SY, Park SY, Kim SU. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00604-2. [PMID: 34091048 DOI: 10.1016/j.cgh.2021.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
71 Park S, You MW, Kang HJ, Moon SK, Park SJ. Contrast-Enhanced Ultrasound for Focal Hepatic Lesions: When to Use and How to Differentiate Lesions? Ultrasound Q 2020;36:224-34. [PMID: 32890325 DOI: 10.1097/RUQ.0000000000000475] [Reference Citation Analysis]
72 Wang F, Numata K, Nakano M, Tanabe M, Chuma M, Nihonmatsu H, Nozaki A, Ogushi K, Luo W, Ruan L, Okada M, Otani M, Inayama Y, Maeda S. Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma. Diagnostics (Basel) 2020;10:E321. [PMID: 32438701 DOI: 10.3390/diagnostics10050321] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
73 Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020;9:E281. [PMID: 31968558 DOI: 10.3390/jcm9010281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
74 Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S. Application of new ultrasound techniques for focal liver lesions. J Med Ultrason (2001) 2020;47:215-37. [PMID: 31950396 DOI: 10.1007/s10396-019-01001-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
75 Jeong WK. [Radiologic Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:261-7. [PMID: 34824184 DOI: 10.4166/kjg.2021.138] [Reference Citation Analysis]
76 Lee J, Sung PS, Yang H, Lee SK, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Bae SH, Choi JY, Yoon SK. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. J Clin Med 2020;9:E4121. [PMID: 33371271 DOI: 10.3390/jcm9124121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
77 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
78 Hwang JA, Min JH, Kang TW, Jeong WK, Kim YK, Ko SE, Choi SY. Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. Eur Radiol 2021. [PMID: 33856517 DOI: 10.1007/s00330-021-07897-8] [Reference Citation Analysis]
79 Iezzi R, Posa A, Tanzilli A, Carchesio F, Pompili M, Manfredi R. Balloon-Occluded MWA (b-MWA) Followed by Balloon-Occluded TACE (b-TACE): Technical Note on a New Combined Single-Step Therapy for Single Large HCC. Cardiovasc Intervent Radiol 2020;43:1702-7. [PMID: 32676963 DOI: 10.1007/s00270-020-02583-6] [Reference Citation Analysis]
80 Cho HJ, Baek GO, Seo CW, Ahn HR, Sung S, Son JA, Kim SS, Cho SW, Jang JW, Nam SW, Cheong JY, Eun JW. Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. Cancer Med 2020;9:5459-72. [PMID: 32537885 DOI: 10.1002/cam4.3230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
81 Younossi ZM, Felix S, Jeffers T, Younossi E, Nader F, Pham H, Afendy A, Cable R, Racila A, Younoszai Z, Lam BP, Golabi P, Henry L, Stepanova M. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2021;4:e2123923. [PMID: 34529067 DOI: 10.1001/jamanetworkopen.2021.23923] [Reference Citation Analysis]
82 Cho Y, Park MJ, Kim K, Kim SW, Kim W, Oh S, Lee JH. Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma. World J Gastroenterol 2020; 26(42): 6599-6613 [PMID: 33268949 DOI: 10.3748/wjg.v26.i42.6599] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
83 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
84 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
85 Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-51. [PMID: 32492765 DOI: 10.3350/cmh.2020.0004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
86 Zou X, Luo Y, Morelli JN, Hu X, Shen Y, Hu D. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Abdom Radiol (NY) 2021;46:3168-78. [PMID: 33660040 DOI: 10.1007/s00261-021-02996-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:513-27. [PMID: 34104640 DOI: 10.2147/JHC.S268288] [Reference Citation Analysis]
88 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
89 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel) 2020;12:E3347. [PMID: 33198216 DOI: 10.3390/cancers12113347] [Reference Citation Analysis]
91 Sung PS, Cho SW, Lee J, Yang H, Jang JW, Bae SH, Choi JY, Yoon SK. Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma. J Liver Cancer 2020;20:128-34. [DOI: 10.17998/jlc.20.2.128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Reference Citation Analysis]
93 Yangdan CR, Wang C, Zhang LQ, Ren B, Fan HN, Lu MD. Recent advances in ultrasound in the diagnosis and evaluation of the activity of hepatic alveolar echinococcosis. Parasitol Res 2021;120:3077-82. [PMID: 34370071 DOI: 10.1007/s00436-021-07262-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Rhee H, Cho E, Nahm JH, Jang M, Chung YE, Baek S, Lee S, Kim M, Park M, Han DH, Choi J, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Journal of Hepatology 2021;74:109-21. [DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
95 Eun JW, Seo CW, Baek GO, Yoon MG, Ahn HR, Son JA, Sung S, Kim DW, Kim SS, Cho HJ, Cheong JY. Circulating Exosomal MicroRNA-1307-5p as a Predictor for Metastasis in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3819. [PMID: 33352935 DOI: 10.3390/cancers12123819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
96 Zhan S, Yang P, Zhou S, Xu Y, Xu R, Liang G, Zhang C, Chen X, Yang L, Jin F, Wang Y. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis. Front Med 2022. [PMID: 35416630 DOI: 10.1007/s11684-022-0920-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Rong D, Liu W, Kuang S, Xie S, Chen Z, Chen F, Xie Q, Luo Q, He B, Zhang Y, Deng Y, Yang H, Chen S, Wang J. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI. Eur Radiol 2021. [PMID: 33860826 DOI: 10.1007/s00330-021-07891-0] [Reference Citation Analysis]